A Phase 1 interventional study of E2086 and Placebo in Healthy Volunteers, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-02.
Sponsored by Eisai Inc. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the safety and tolerability of E2086 following administration of a single oral doses in healthy adult and elderly participants.
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All females who are of :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 1 milligram (mg) (2\*0.5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
Drug: E2086 · Drug: Placebo
Participants will receive 2.5 mg (5\*0.5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
Drug: E2086 · Drug: Placebo
Participants will receive 5 mg (1\*5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
Drug: E2086 · Drug: Placebo
Participants will receive 10 mg (2\*5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
Drug: E2086 · Drug: Placebo
Participants will receive 25 mg (1\*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
Drug: E2086 · Drug: Placebo
Participants will receive 50 mg (2\*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
Drug: E2086 · Drug: Placebo
Participants will receive 100 mg (4\*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
Drug: E2086 · Drug: Placebo
Participants will receive 25 mg (1\*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
Drug: E2086 · Drug: Placebo
E2086 tablets.
E2086 matched placebo tablets.
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: From Screening up to 10 days
Number of Participants With Serious Adverse Events (SAEs)
Time frame: From Screening up to 10 days
Number of Participants With Clinically Significant Abnormal Laboratory Values
Time frame: From Screening up to 10 days
Number of Participants With Clinically Significant Abnormal Vital Signs Values
Time frame: From Screening up to 10 days
Number of Participants With Clinically Significant Abnormal Electrocardiograms (ECGs) Findings
Time frame: From Screening up to 10 days
Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-suicide Severity Rating Scale (C-SSRS)
The C-SSRS is an interview-based rating scale to systematically assess any suicidality, suicidal behavior, or suicidal ideation. Any suicidality is emergence of any suicidal ideation or suicidal behavior. Any suicidal behavior is indicated when response is "yes" for any these questions- actual attempt to suicide, engaged in non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts. Any suicidal ideation is indicated when response is "yes" for any of these questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide.
Time frame: From Screening up to 10 days
Number of Participants With Clinically Significant Abnormal Physical Examination Findings
Time frame: From Screening up to 10 days
Number of Participants With Clinically Significant Abnormal Neurological Examination Findings
Time frame: From Screening up to 10 days
Number of Participants With Clinically Significant Abnormal Electroencephalogram (EEG) Findings
Time frame: Baseline, Days 1 and 2
Cmax: Maximum Observed Plasma Concentration for E2086 and its Metabolites
Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose
Tmax: Time to Reach Maximum Observed Plasma Concentration (Cmax) for E2086 and its Metabolites
Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose
AUC(0-24h): Area Under the Plasma Concentration-time Curve From Time Zero to 24 hours Post-dose for E2086 and its Metabolites
Time frame: Day 1: Pre-dose (0 hour) up to 24 hours post-dose
AUC(0-t): Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration for E2086 and its Metabolites
Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose
AUC(0-72h): Area Under the Plasma Concentration-time Curve From Time Zero to 72 hours Post-dose for E2086 and its Metabolites
Time frame: Day 1: Pre-dose (0 hour) up to 72 hours post-dose
AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time Zero to Infinite for E2086 and its Metabolites
Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose
t1/2: Terminal Elimination Phase Half-life for E2086 and its Metabolites
Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose
CL/F: Apparent Total Clearance for E2086
Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose
Vz/F: Apparent Volume of Distribution at Terminal Phase for E2086
Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose
MRp: Ratio of Plasma AUC(0-inf) of Metabolite to E2082, Corrected for Molecular Weights
Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose
Mean Change in Subjective Sleep Onset Latency (sSOL)
sSOL is a participant-reported estimate of the amount of time (in minutes) it took the participant to fall asleep the prior evening.
Time frame: Screening up to Study Day 7
Ae: Cumulative Amount of E2086 and its Metabolites Excreted in Urine
Time frame: Day 1: Pre-dose (0 hour) up to 120 hours post-dose
CLR: Renal Clearance of E2086 and its Metabolites
Time frame: Day 1: Pre-dose (0 hour) up to 120 hours post-dose
Fe: Percent (%) of E2086 and its Metabolites Excreted in Urine
Time frame: Day 1: Pre-dose (0 hour) up to 120 hours post-dose
MRU: Ratio of Ae Urine Concentration of Metabolite to E2082, Corrected for Molecular Weights
Time frame: Day 1: Pre-dose (0 hour) up to 120 hours post-dose
Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.
No publications or documents are linked to this record.
Ran from Feb 2023 to primary completion in Jan 2024, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ledasorexton